Real-world outcomes by race in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Final analysis results from the informCLL registry.

被引：0
|
作者：
Barrientos, Jacqueline Claudia
Sharman, Jeff Porter
Gutierrez, Meghan E.
Wu, Linda
Qureshi, Zaina P.
Raz, Anat
Girardi, Vincent
Naganuma, Maoko
Ghosh, Nilanjan
机构：
[1] Mt Sinai Comprehens Canc Ctr, Miami Beach, FL USA
[2] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
[3] Lymphoma Res Fdn, New York, NY USA
[4] Janssen, Horsham, PA USA
[5] Janssen Sci Affairs LLC, Horsham, PA USA
[6] Pharmacyclics LLC, San Francisco, CA USA
[7] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7536
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world healthcare resource utilization (HRU)/costs associated with venetoclax treatment among chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients.
    Rogers, Kerry Anne
    Emond, Bruno
    Manceur, Ameur M.
    Kinkead, Frederic
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry
    Mato, Anthony R.
    Ghosh, Nilanjan
    Sharman, Jeff P.
    Brander, Danielle
    Gutierrez, Meghan
    Huang, Qing
    Wu, Linda H.
    Young, Alex
    Upasani, Sandhya
    Naganuma, Maoko
    Barrientos, Jacqueline C.
    BLOOD ADVANCES, 2023, 7 (17) : 4760 - 4764
  • [33] Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
    Barr, Paul M.
    Munir, Talha
    Brown, Jennifer R.
    O'Brien, Susan Mary
    Barrientos, Jacqueline Claudia
    Reddy, Nishitha M.
    Coutre, Steven
    Tam, Constantine Si Lun
    Mulligan, Stephen P.
    Jager, Ulrich
    Kipps, Thomas J.
    Moreno, Carol
    Montillo, Marco
    Burger, Jan Andreas
    Byrd, John C.
    Hillmen, Peter
    Dai, Sandra
    Szoke, Anita
    Dean, James P.
    Woyach, Jennifer Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] The Immunophenotype of Prolymphocytoid Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Revisited
    Rathke, S. K.
    Chang, J. C.
    Harrington, A. M.
    Olteanu, H.
    Kroft, S. H.
    MODERN PATHOLOGY, 2013, 26 : 357A - 357A
  • [35] Real-world outcomes following adverse events and dose reduction of first-line ibrutinib in Medicare beneficiaries with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Shadman, Mazyar
    Srivastava, Bhavini P.
    Salkar, Monika
    Saifan, Chadi
    Agatep, Barnabie C.
    Jones, Barton
    Ryan, Olga
    Bacchus, Shaffee
    Stephens, Deborah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] The Immunophenotype of Prolymphocytoid Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Revisited
    Rathke, S. K.
    Chang, J. C.
    Harrington, A. M.
    Olteanu, H.
    Kroft, S. H.
    LABORATORY INVESTIGATION, 2013, 93 : 357A - 357A
  • [37] Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices
    Hou, Jing-Zhou
    Blanc, Simon
    Maglinte, Gregory A.
    Vasudevan, Anupama
    Rui, Anna
    Gart, Mike
    Pham, Hoa
    Aton, Lindsay
    Wang, Brandon
    Choksi, Rushir J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] IDELALISIB IN COMBINATION WITH RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): REAL-WORLD EXPERIENCE THROUGH AN EARLY ACCESS PROGRAM IN EUROPE AND AUSTRALIA
    Li, J. J.
    Yong, A. S.
    Justicia, J. L.
    Smith, C.
    Delgado, J.
    HAEMATOLOGICA, 2016, 101 : 229 - 229
  • [39] Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Jaglowski, Samantha M.
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Woyach, Jennifer A.
    Blum, Kristie A.
    Greyer, Michael R.
    Geyer, Susan Michelle
    Heerema, Nyla A.
    Lozanski, Gerard
    Stefanos, Mona
    Hall, Nathan
    Nagar, Veena
    Munneke, Brian
    West, Jamie-Sue
    Neuenburg, Jutta K.
    James, Danelle F.
    Johnson, Amy J.
    Byrd, John C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S206 - S207
  • [40] Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Coutre, Steven
    Byrd, John C.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Devereux, Stephen
    Robak, Tadeusz
    Kipps, Thomas J.
    Schuh, Anna
    Moreno, Carol
    Furman, Richard R.
    Burger, Jan
    O'Dwyer, Michael
    Ghia, Paolo
    Valentino, Rudolph
    Suzuki, Samuel
    Ninomoto, Joi
    James, Danelle F.
    O'Brien, Susan M.
    BLOOD, 2016, 128 (22)
12345